Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTR4 | Q13639 | 9/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598401 | 0.94 | HTR4 (0.58) | RAB9AHTR4CYP2D6CYP3A4CHRM2 | |
| SCHEMBL598870 | 0.89 | RAB9A (0.54) | RAB9AHTR4CYP2D6CHRM2ADRA2A | |
| SCHEMBL1629678 | 0.88 | RAB9A (0.53) | RAB9AHTR4CYP2D6CYP3A4CHRM2 | |
| SCHEMBL598679 | 0.88 | RAB9A (0.53) | RAB9AHTR4CYP2D6CHRM2ADRA2A | |
| SCHEMBL599152 | 0.87 | RAB9A (0.53) | RAB9AHTR4CYP2D6CYP3A4CHRM2 | |
| SCHEMBL597784 | 0.87 | HTR4 (0.53) | RAB9AHTR4CYP2D6CYP3A4CHRM2 | |
| SCHEMBL597410 | 0.87 | RAB9A (0.53) | RAB9AHTR4CYP2D6CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL598346 | 0.87 | RAB9A (0.53) | RAB9AHTR4CYP2D6CYP3A4CHRM2 | |
| SCHEMBL599038 | 0.87 | RAB9A (0.54) | RAB9AHTR4CYP2D6CHRM2ADRA2A | |
| SCHEMBL598056 | 0.86 | RAB9A (0.52) | RAB9AHTR4CYP2D6CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | claimed |
| EP-2445877-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Nanotherapeutics, Inc. (US) | 2012-05-02 | — | — | EP | claimed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | claimed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | claimed |
| WO-2010065743-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| EP-2445877-B1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS INC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2445877-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Nanotherapeutics, Inc. (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | NANOTHERAPEUTICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8114894-B2 | Bicyclic compounds and methods of making and using same | NANOTHERAPEUTICS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOSHIFT, LLC | 2010-08-05 | — | — | US | disclosed |
| WO-2010065743-A2 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | NANOTHERAPEUTICS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088793-A1 | Bicyclic Compounds and Methods of Making and Using Same | HTR2C, HTR3A, HTR3C | RAB9A 3526/4885HTR4 7/4885CYP2D6 381/4885 |
| US-20100197723-A1 | BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | HTR2C, HTR3A, HTR3C | RAB9A 3526/4885HTR4 7/4885CYP2D6 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.